Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer.

Targeted therapy revolutionized cancer treatment, with gene fusions leading the way when the FDA approved imatinib in 2001 to ...

EMA committee recommends approval of Bristol Myers’ repotrectinib to treat advanced ROS1-positive NSCLC & NTRK-positive solid tumours: Princeton, New Jersey Monday, November 18, ...

Bristol Myers Squibb (BMY) has received a recommendation for approval from an expert panel of the European Medicines Agency ...

Bristol Myers Squibb on Friday said the European Medicines Agency's Committee for Medicinal Products for Human Use recommended expanded approval of its Augtyro cancer drug in a pair of indications.

Illumina raised the curtain on a revamp of its flagship tumor profiling test, which aims to offer faster turnarounds, fewer ...

The detection of MRD mutations in postoperative plasma samples was also found to be associated with patient prognosis, with patients having fusion ... small cell lung cancer with gene fusions ...

The committee recommended that the drug be approved for the treatment of adults with ROS1-positive advanced non-small cell lung cancer ... expressing a NTRK gene fusion, according to a statement.

Squibb announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended ...

Now, it's up to the European Commission to confirm those potential green lights in the coming weeks and months.

Novotech, the global full-service clinical Contract Research Organization (CRO), has published a new report, Small Cell Lung Cancer: Global Clinical Trial Landscape 2024, providing an in-depth ...

This action prevents the oncogenic fusion proteins from triggering gene expression. Additionally ... a second NDA was accepted by the NMPA for first-line treatment of ROS1-positive lung cancer.